Hospital

The Rite Aid Foundation is awarding $2.3 million to Children’s Miracle Network Hospitals through its KidCents Grant Program.

To date, the FDA has granted rivaroxaban 8 indications, 6 of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of venous thromboemolism across a wide range of patient populations.

A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.

Top news of the week from Specialty Pharmacy Times.

This article is the third in a series on difficult to pronounce drug names.

Officials from the FDA have allowed marketing of a rapid diagnostic test (RDT) to help detect Ebola virus antigens in the bloodstream from certain living individuals and samples from recently deceased individuals suspected to have Ebola.

Top news of the day from across the health care landscape.

A recent study has revealed that just under half of the US population fears random mass shootings and terrorist attacks.

A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.

The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Two lawsuits against the FDA have been resolved in a conclusion favorable to Endo International, which argued that vasporessin should be excluded from the agency’s compounding list.

Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.

Johnson & Johnson and its Janssen Pharmaceutical Cos unit have agreed to a more than $10 million settlement, rather than allowing the matter go to federal trial.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.

Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.

A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

New data confirm high activity of larotrectinib in pediatric and adult patients with TRK fusion cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.

Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.